Vaccine coverage and effectiveness against laboratory-confirmed symptomatic and severe Covid-19 in indigenous people in Brazil: a cohort study
| Autor(a) principal: | |
|---|---|
| Data de Publicação: | 2022 |
| Outros Autores: | , , , , , , , , , , , |
| Tipo de documento: | Artigo |
| Idioma: | eng |
| Título da fonte: | Repositório Institucional da FIOCRUZ (ARCA) |
| Texto Completo: | https://www.arca.fiocruz.br/handle/icict/57588 |
Resumo: | Fundação Oswaldo Cruz. Instituto Gonçalo Muniz. Centro de Integração de Dados e Conhecimentos para a Saúde. Salvador, BA, Brasil / London School of Hygiene and Tropical Medicine. London, United Kingdom. |
| id |
CRUZ_59a84f587fb944249ed9ea135f1f3800 |
|---|---|
| oai_identifier_str |
oai:www.arca.fiocruz.br:icict/57588 |
| network_acronym_str |
CRUZ |
| network_name_str |
Repositório Institucional da FIOCRUZ (ARCA) |
| repository_id_str |
2135 |
| spelling |
Pescarini, Julia M.Cardoso, Andrey MoreiraSantos, Ricardo VenturaScaff, PriscilaPaixao, Enny S.Ranzani, Otavio T.Silva, Thiago CerqueiraBoaventura, Viviane S.Bertoldo Junior, JuracyOliveira, Vinicius de A.Werneck, Guilherme L.Barreto, Mauricio L.Barral Netto, Manoel2023-03-27T14:08:27Z2023-03-27T14:08:27Z2022PESCARINI, Julia M. et al. Vaccine coverage and effectiveness against laboratory-confirmed symptomatic and severe Covid-19 in indigenous people in Brazil: a cohort study. The Lancet, p. 1-19, 2022.0140-6736https://www.arca.fiocruz.br/handle/icict/5758810.2139/ssrn.4224510engElsevierCOVID-19PandemiaEficácia da vacinaCobertura vacinalEstudo de coortePessoas indígenasServiços de saúdePopulação indígenaSaúde dos indígenasAmeríndiosíndiosSul AmericanoGrupos vulneráveisTransmissão de doenças infecciosasBrasilCOVID-19PandemicVaccine effectivenessVaccine coverageCohort studyIndigenous peoplesHealth servicesIndigenous populationHealth of indigenous peopleAmerindsIndiansSouth AmericanVulnerable groupsInfectious disease transmissionBrazilVaccine coverage and effectiveness against laboratory-confirmed symptomatic and severe Covid-19 in indigenous people in Brazil: a cohort studyinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleFundação Oswaldo Cruz. Instituto Gonçalo Muniz. Centro de Integração de Dados e Conhecimentos para a Saúde. Salvador, BA, Brasil / London School of Hygiene and Tropical Medicine. London, United Kingdom.Fundação Oswaldo Cruz. Escola Nacional de Saúde Pública. Rio de Janeiro, RJ, Brasil.Fundação Oswaldo Cruz. Escola Nacional de Saúde Pública. Rio de Janeiro, RJ, Brasil / Universidade Federal do Rio de Janeiro. Museu Nacional. Rio de Janeiro, RJ, Brasil.Fundação Oswaldo Cruz. Instituto Gonçalo Muniz. Centro de Integração de Dados e Conhecimentos para a Saúde. Salvador, BA, Brasil.Fundação Oswaldo Cruz. Instituto Gonçalo Muniz. Centro de Integração de Dados e Conhecimentos para a Saúde. Salvador, BA, Brasil / London School of Hygiene and Tropical Medicine. London, United Kingdom.Barcelona Institute for Global Health. ISGlobal. Universitat Pompeu Fabra (UPF). CIBER Epidemiología y Salud Pública (CIBERESP). Barcelona, Spain / Universidade de São Paulo. Faculdade de Medicina. Instituto do Coração. Hospital das Clínicas. Divisão Pulmonar. São Paulo, SP, Brasil.Universidade Federal da Bahia. Salvador, BA, Brasil / Fundação Oswaldo Cruz. Instituto Gonçalo Muniz. Laboratórios LIB e LEITV. Salvador, BA, Brasil.Universidade Federal da Bahia. Salvador, BA, Brasil / Fundação Oswaldo Cruz. Instituto Gonçalo Muniz. Laboratórios LIB e LEITV. Salvador, BA, Brasil.Fundação Oswaldo Cruz. Instituto Gonçalo Muniz. Centro de Integração de Dados e Conhecimentos para a Saúde. Salvador, BA, Brasil / Barcelona Institute for Global Health. ISGlobal. Universitat Pompeu Fabra (UPF). CIBER Epidemiología y Salud Pública (CIBERESP). Barcelona, Spain / Universidade Federal da Bahia. Salvador, BA, Brasil.Fundação Oswaldo Cruz. Instituto Gonçalo Muniz. Centro de Integração de Dados e Conhecimentos para a Saúde. Salvador, BA, Brasil / Universidade Federal da Bahia. Salvador, BA, Brasil / Fundação Oswaldo Cruz. Instituto Gonçalo Muniz. Laboratórios LIB e LEITV. Salvador, BA, Brasil.Universidade do Estado do Rio de Janeiro. Rio de Janeiro, RJ, Brasil / Universidade Federal do Rio de Janeiro. Rio de Janeiro, RJ, Brasil.Fundação Oswaldo Cruz. Instituto Gonçalo Muniz. Centro de Integração de Dados e Conhecimentos para a Saúde. Salvador, BA, Brasil.Fundação Oswaldo Cruz. Instituto Gonçalo Muniz. Centro de Integração de Dados e Conhecimentos para a Saúde. Salvador, BA, Brasil / Universidade Federal da Bahia. Salvador, BA, Brasil / Fundação Oswaldo Cruz. Instituto Gonçalo Muniz. Laboratórios LIB e LEITV. Salvador, BA, Brasil.Background: We estimated the coverage and effectiveness of Covid-19 vaccines against laboratory-confirmed Covid-19 cases among indigenous people in Brazil. Methods: We linked nationwide immunization data with symptomatic and Severe Acute Respiratory Infection records and studied a cohort of vaccinated indigenous people aged ≥5 years between 18th Jan 2021 and 1st Mar 2022. We estimated the Covid-19 vaccination coverage and used Poisson regression to calculate the vaccine effectiveness (VE) of CoronaVac, ChAdOx1, and BNT162b2 against Covid-19 laboratory-confirmed symptomatic and severe cases (i.e., mortality, hospitalisation, and hospital-progression to Intensive Care Unit (ICU) or death). VE was estimated as (1-RR)*100, comparing unexposed (<14 days after the 1st dose), to partially (≥14 days after 1st dose to <14 days after 2nd dose), or fully vaccinated (≥14 days after 2nd dose). Findings: By 1st Mar 2022, 48·7% (35·0-62·3) of eligible indigenous people vs 74·8% (57·9-91·8) overall Brazilians had been fully vaccinated for Covid-19. Among the 370,092 indigenous subjects studied, we detected 1951 Covid-19 cases, of which 105 were hospitalised and 35 died. VE for the three Covid-19 vaccines combined was 53% (95%CI:44-60%) for symptomatic cases, 53% (95%CI:-56-86%) for mortality and 41% (95%CI:-35-75%) for hospitalisation. Among hospitalised patients, VE was 87% (95%CI:27-98%) for progression to ICU and 96% (95%CI: 90-99%) for death. Interpretation: Lower coverage but similar Covid-19 vaccine effectiveness among indigenous people than overall Brazilians suggest the need to expand access, timely vaccination, especially among children and adolescents, and urgently offer booster doses to achieve a great level of protection among this group.info:eu-repo/semantics/openAccessreponame:Repositório Institucional da FIOCRUZ (ARCA)instname:Fundação Oswaldo Cruz (FIOCRUZ)instacron:FIOCRUZLICENSElicense.txtlicense.txttext/plain; charset=utf-82991https://www.arca.fiocruz.br/bitstream/icict/57588/1/license.txt5a560609d32a3863062d77ff32785d58MD51ORIGINALPescarin_Julia_etal IGM_2022_PREPRINT.pdfPescarin_Julia_etal IGM_2022_PREPRINT.pdfapplication/pdf256138https://www.arca.fiocruz.br/bitstream/icict/57588/2/Pescarin_Julia_etal%20IGM_2022_PREPRINT.pdff6bc13d9e126685af219eae41028894aMD52icict/575882023-04-11 11:33:36.512oai:www.arca.fiocruz.br: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ório InstitucionalPUBhttps://www.arca.fiocruz.br/oai/requestrepositorio.arca@fiocruz.bropendoar:21352023-04-11T14:33:36Repositório Institucional da FIOCRUZ (ARCA) - Fundação Oswaldo Cruz (FIOCRUZ)false |
| dc.title.en_US.fl_str_mv |
Vaccine coverage and effectiveness against laboratory-confirmed symptomatic and severe Covid-19 in indigenous people in Brazil: a cohort study |
| title |
Vaccine coverage and effectiveness against laboratory-confirmed symptomatic and severe Covid-19 in indigenous people in Brazil: a cohort study |
| spellingShingle |
Vaccine coverage and effectiveness against laboratory-confirmed symptomatic and severe Covid-19 in indigenous people in Brazil: a cohort study Pescarini, Julia M. COVID-19 Pandemia Eficácia da vacina Cobertura vacinal Estudo de coorte Pessoas indígenas Serviços de saúde População indígena Saúde dos indígenas Ameríndios índios Sul Americano Grupos vulneráveis Transmissão de doenças infecciosas Brasil COVID-19 Pandemic Vaccine effectiveness Vaccine coverage Cohort study Indigenous peoples Health services Indigenous population Health of indigenous people Amerinds Indians South American Vulnerable groups Infectious disease transmission Brazil |
| title_short |
Vaccine coverage and effectiveness against laboratory-confirmed symptomatic and severe Covid-19 in indigenous people in Brazil: a cohort study |
| title_full |
Vaccine coverage and effectiveness against laboratory-confirmed symptomatic and severe Covid-19 in indigenous people in Brazil: a cohort study |
| title_fullStr |
Vaccine coverage and effectiveness against laboratory-confirmed symptomatic and severe Covid-19 in indigenous people in Brazil: a cohort study |
| title_full_unstemmed |
Vaccine coverage and effectiveness against laboratory-confirmed symptomatic and severe Covid-19 in indigenous people in Brazil: a cohort study |
| title_sort |
Vaccine coverage and effectiveness against laboratory-confirmed symptomatic and severe Covid-19 in indigenous people in Brazil: a cohort study |
| author |
Pescarini, Julia M. |
| author_facet |
Pescarini, Julia M. Cardoso, Andrey Moreira Santos, Ricardo Ventura Scaff, Priscila Paixao, Enny S. Ranzani, Otavio T. Silva, Thiago Cerqueira Boaventura, Viviane S. Bertoldo Junior, Juracy Oliveira, Vinicius de A. Werneck, Guilherme L. Barreto, Mauricio L. Barral Netto, Manoel |
| author_role |
author |
| author2 |
Cardoso, Andrey Moreira Santos, Ricardo Ventura Scaff, Priscila Paixao, Enny S. Ranzani, Otavio T. Silva, Thiago Cerqueira Boaventura, Viviane S. Bertoldo Junior, Juracy Oliveira, Vinicius de A. Werneck, Guilherme L. Barreto, Mauricio L. Barral Netto, Manoel |
| author2_role |
author author author author author author author author author author author author |
| dc.contributor.author.fl_str_mv |
Pescarini, Julia M. Cardoso, Andrey Moreira Santos, Ricardo Ventura Scaff, Priscila Paixao, Enny S. Ranzani, Otavio T. Silva, Thiago Cerqueira Boaventura, Viviane S. Bertoldo Junior, Juracy Oliveira, Vinicius de A. Werneck, Guilherme L. Barreto, Mauricio L. Barral Netto, Manoel |
| dc.subject.other.en_US.fl_str_mv |
COVID-19 Pandemia Eficácia da vacina Cobertura vacinal Estudo de coorte Pessoas indígenas Serviços de saúde População indígena Saúde dos indígenas Ameríndios índios Sul Americano Grupos vulneráveis Transmissão de doenças infecciosas Brasil |
| topic |
COVID-19 Pandemia Eficácia da vacina Cobertura vacinal Estudo de coorte Pessoas indígenas Serviços de saúde População indígena Saúde dos indígenas Ameríndios índios Sul Americano Grupos vulneráveis Transmissão de doenças infecciosas Brasil COVID-19 Pandemic Vaccine effectiveness Vaccine coverage Cohort study Indigenous peoples Health services Indigenous population Health of indigenous people Amerinds Indians South American Vulnerable groups Infectious disease transmission Brazil |
| dc.subject.en.en_US.fl_str_mv |
COVID-19 Pandemic Vaccine effectiveness Vaccine coverage Cohort study Indigenous peoples Health services Indigenous population Health of indigenous people Amerinds Indians South American Vulnerable groups Infectious disease transmission Brazil |
| description |
Fundação Oswaldo Cruz. Instituto Gonçalo Muniz. Centro de Integração de Dados e Conhecimentos para a Saúde. Salvador, BA, Brasil / London School of Hygiene and Tropical Medicine. London, United Kingdom. |
| publishDate |
2022 |
| dc.date.issued.fl_str_mv |
2022 |
| dc.date.accessioned.fl_str_mv |
2023-03-27T14:08:27Z |
| dc.date.available.fl_str_mv |
2023-03-27T14:08:27Z |
| dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
| dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article |
| format |
article |
| status_str |
publishedVersion |
| dc.identifier.citation.fl_str_mv |
PESCARINI, Julia M. et al. Vaccine coverage and effectiveness against laboratory-confirmed symptomatic and severe Covid-19 in indigenous people in Brazil: a cohort study. The Lancet, p. 1-19, 2022. |
| dc.identifier.uri.fl_str_mv |
https://www.arca.fiocruz.br/handle/icict/57588 |
| dc.identifier.issn.none.fl_str_mv |
0140-6736 |
| dc.identifier.doi.none.fl_str_mv |
10.2139/ssrn.4224510 |
| identifier_str_mv |
PESCARINI, Julia M. et al. Vaccine coverage and effectiveness against laboratory-confirmed symptomatic and severe Covid-19 in indigenous people in Brazil: a cohort study. The Lancet, p. 1-19, 2022. 0140-6736 10.2139/ssrn.4224510 |
| url |
https://www.arca.fiocruz.br/handle/icict/57588 |
| dc.language.iso.fl_str_mv |
eng |
| language |
eng |
| dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
| eu_rights_str_mv |
openAccess |
| dc.publisher.none.fl_str_mv |
Elsevier |
| publisher.none.fl_str_mv |
Elsevier |
| dc.source.none.fl_str_mv |
reponame:Repositório Institucional da FIOCRUZ (ARCA) instname:Fundação Oswaldo Cruz (FIOCRUZ) instacron:FIOCRUZ |
| instname_str |
Fundação Oswaldo Cruz (FIOCRUZ) |
| instacron_str |
FIOCRUZ |
| institution |
FIOCRUZ |
| reponame_str |
Repositório Institucional da FIOCRUZ (ARCA) |
| collection |
Repositório Institucional da FIOCRUZ (ARCA) |
| bitstream.url.fl_str_mv |
https://www.arca.fiocruz.br/bitstream/icict/57588/1/license.txt https://www.arca.fiocruz.br/bitstream/icict/57588/2/Pescarin_Julia_etal%20IGM_2022_PREPRINT.pdf |
| bitstream.checksum.fl_str_mv |
5a560609d32a3863062d77ff32785d58 f6bc13d9e126685af219eae41028894a |
| bitstream.checksumAlgorithm.fl_str_mv |
MD5 MD5 |
| repository.name.fl_str_mv |
Repositório Institucional da FIOCRUZ (ARCA) - Fundação Oswaldo Cruz (FIOCRUZ) |
| repository.mail.fl_str_mv |
repositorio.arca@fiocruz.br |
| _version_ |
1813009295782969344 |